Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
V.ARCH
Alternate Symbol(s):
ACHFF
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is...
LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(260)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 30, 2023 9:04am
Raymond James Analyst
One needs to consider that our one sole analyst from Raymond James has been waiting for the release of independent third party review report on phase 2 trial. Now we know Health Canada has seen data
...more
(2)
•••
2019champs
X
View Profile
View Bullboard History
Comment by
2019champs
on Jun 29, 2023 8:19pm
RE:Fire Sale
The data is long overdue. Once P2 data is released and if analysts find it promising, we will likely get an upgrade on the stock. This will open up alot of buying opportunities. Hopefully we aren'
...more
(260)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 29, 2023 3:11pm
Fire Sale
Time to add more. Month end here, margin calls triggered. This is such a screaming buy, so undervalued, to have FDA approval for AKI phase 2 trial this should be up 100% minimum. We should be at $10
...more
(260)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 28, 2023 8:31pm
Somethings smells here
Yesterday's new release of FDA approval for AKI phase 2 trial should have caught the attention of any interested investors. IMO yesterdays news should have got us back up to $5 with high volume
...more
(260)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 27, 2023 5:32pm
Wild Ride Today
Well I told everybody to buckle up and you sure beeded your seat belt today. $2:14 to $2.38 in the first hour then the shorts stepped back in and quickly knocked in back down to $2.18. We slowly
...more
(9)
•••
Riverfolk
X
View Profile
View Bullboard History
Comment by
Riverfolk
on Jun 27, 2023 10:17am
RE:News - ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA
Recent funding contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) announced by the Company in March 2023, will significantly help cover
...more
(9)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Jun 27, 2023 9:38am
News - ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA
June 27 (Reuters) - Arch Biopartners Inc: * ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA TO PROCEED WITH PHASE II ACUTE KIDNEY INJURY TRIAL * ARCH BIOPARTNERS INC - CS-AKI TRIAL HAS PLANS TO
...more
(9)
•••
Riverfolk
X
View Profile
View Bullboard History
Comment by
Riverfolk
on Jun 27, 2023 9:11am
RE:New Press Release - Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
"The IND application included preclinical data, Phase I and Phase II clinical data to date, manufacturing processes, and the protocol design for the CS-AKI Phase II trial."
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 27, 2023 7:16am
New Press Release - Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to mediate organ inflammation in the lungs, liver and kidneysThere are currently no treatments available...
read article.
(260)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 26, 2023 4:23pm
Nice Push from Anonymous
The last hour of trading lived up to its name of Power Hour. Anonymous was aggressively buying into the close. I think someone knows something here. The tide is turning here folks, the train is
...more
(260)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 24, 2023 12:46pm
Big Week Ahead
Well we are down crunch time here. Management is under the microscope here. They told the markets that phase 2 independent data review would be out before the end of 1st half 2023. So will management
...more
(260)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 21, 2023 2:48pm
Big Buy Orders
I just checked level 2. There are two very large buy orders. 100,000 at $1.88 150,000 at $1.93 Thats a positive sign and obviously someone is very bullish on the stock.
(260)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 20, 2023 2:43pm
Adding Shares
For those who actually read this bullboard or follow this stock, today is a gift with our shorts returning and knocking us back below $2. This low ball share price will not last much longer. We are
...more
(260)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 20, 2023 1:29pm
Shorts are Back
Well we had a brief break yesterday with CIBC and Scotiabank. Neither house was active yesterday selling but CIBC is back today. The fact US markets were closed yesterday might suggest the sellers
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
One Property, One Focus on Advancing this Gold Project in Ontario